08:10 AM EDT, 03/28/2024 (MT Newswires) -- Theratechnologies Inc. ( THTX ) on Thursday announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, demonstrating the potential of its SORT1+ TechnologyTM platform - including novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as anticancer treatments. The AACR meeting is taking place April 5-10 in San Diego, CA.

"The studies we are presenting at the AACR 2024 meeting highlight the significant advancements made on our SORT+1 TechnologyTM platform through careful assessment of investigational compounds, including sudocetaxel zendusortide, which is currently being evaluated in a Phase 1 trial in patients with advanced ovarian cancer," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies ( THTX ). "These data showcase the potential of our PDC candidates with different payloads as potential future treatment options for a broad range of cancer types."